Microbiome in Lung Cancer and Other Malignancies
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 1/16/2019 |
| Start Date: | August 30, 2018 |
| End Date: | August 2019 |
| Contact: | Jun Zhang, MD, PhD |
| Email: | jun-zhang-1@uiowa.edu |
| Phone: | 319-356-2148 |
The Role of Microbiome in Lung Cancer and Other Malignancies
This research study will characterize the nasal, oral, skin and fecal microbiome in patients
with lung cancer and other malignancies, and correlate the data with treatment response and
toxicities of immunotherapy, the tumor genetic and immune profiling, as well as the multiple
-omics in the blood.
with lung cancer and other malignancies, and correlate the data with treatment response and
toxicities of immunotherapy, the tumor genetic and immune profiling, as well as the multiple
-omics in the blood.
Participants will be asked to provide nasal, oral and skin swabs, as well as stool samples
during their regular clinic visits, at the baseline before immunotherapy is given, and at the
time when treatment is changed due to either disease progression or unbearable toxicities
leading to treatment stop/change. The samples will be subjected to DNA extraction followed by
16S rRNA and/or shotgun sequencing metagenomic analysis. The data will be correlated to
clinical response from treatments, toxicities and tissue genetic/immunological
characteristics (mutations, PDL1 expression, etc.), as well as multiple -omics (e.g.
metabolomics, proteomics, etc.) in the blood.
during their regular clinic visits, at the baseline before immunotherapy is given, and at the
time when treatment is changed due to either disease progression or unbearable toxicities
leading to treatment stop/change. The samples will be subjected to DNA extraction followed by
16S rRNA and/or shotgun sequencing metagenomic analysis. The data will be correlated to
clinical response from treatments, toxicities and tissue genetic/immunological
characteristics (mutations, PDL1 expression, etc.), as well as multiple -omics (e.g.
metabolomics, proteomics, etc.) in the blood.
Inclusion Criteria:
- Patients diagnosed with lung cancer and other malignancies who are candidates for
systemic therapies such as immunotherapy and chemotherapy
Exclusion Criteria:
- Pregnant patients
- Patients taking more than 2 alcoholic drinks per day
- Patients using non-medical drugs such as marijuana, cocaine, heroine etc.
We found this trial at
1
site
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
Click here to add this to my saved trials
